India Inhaled Corticosteroids Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Inhaled Corticosteroids Market was valued at USD 183.0 million in 2025 and is projected to reach USD 271.55 million by 2032, growing at a CAGR of approximately 5.8% during 2026–2032.
India Inhaled Corticosteroids Market Highlights
| Report Metric | Details |
| Report Name | India Inhaled Corticosteroids Market |
| Market Size 2025 | USD 183.0 million |
| Market Size 2032 | USD 271.55 million |
| Absolute Growth 2025–2032 | USD 88.55 million |
| CAGR 2026–2032 | 5.8% |
| Peak Annual Growth | 8.2% in 2031 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Drug Name/Form, 2025 | Fluticasone (53% share) |
| Leading Indication, 2025 | Asthma / COPD (40% share) |
| Leading Dosage Delivery, 2025 | MDI (41% share) |
| Leading Distribution Channel, 2025 | Prescription Outlets (48% share) |
| Fastest-Growing Drug Name/Form | Budesonide (8.5% CAGR) |
| Fastest-Growing Indication | Long-Term Inflammation (8.0% CAGR) |
| Fastest-Growing Dosage Delivery | DPI (7.4% CAGR) |
| Fastest-Growing Distribution Channel | Hospital Pharmacies (7.2% CAGR) |
| Growing Sector | Respiratory Health |
| Key End Users | Hospitals, Clinics, Pharmacies |
India Inhaled Corticosteroids Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Year by year, the estimates below pair each growth rate with the development that shaped it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 4.6 | The market showed steady demand due to the high prevalence of respiratory diseases. |
| 2023 | 4.1 | Growth slowed as healthcare access faced challenges in rural areas. |
| 2024 | 5.6 | Demand increased as awareness campaigns on asthma management gained traction. |
| 2025 | 6.9 | Growth accelerated with the introduction of new treatment guidelines for asthma. |
| 2026 | 7.1 | The market is expected to expand as health insurance coverage improves for respiratory treatments. |
| 2027 | 6.5 | Growth will slow due to regulatory delays in new product approvals. |
| 2028 | 3.7 | Demand is expected to decrease as competition intensifies among existing inhaled corticosteroids. |
| 2029 | 7.5 | The market will rebound with rising urbanisation and respiratory health initiatives. |
| 2030 | 3.8 | Growth will slow as economic factors affect healthcare spending. |
| 2031 | 8.2 | Demand is projected to surge with the launch of new inhaled corticosteroid formulations. |
| 2032 | 3.9 | Growth will slow as market maturity begins to set in. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Inhaled Corticosteroids Market Synopsis
The Inhaled Corticosteroids Market in India encompasses medications used primarily for asthma and COPD treatment. These anti-inflammatory drugs are delivered via inhalers or nebulizers, improving respiratory health. The market is expanding due to a high prevalence of respiratory diseases, with around 15 million individuals affected by asthma. Initiatives such as the National Health Mission are enhancing healthcare access, driving demand for inhaled corticosteroids across urban and rural settings. The focus on improving respiratory health services is expected to further boost market growth.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| High prevalence of asthma and COPD drives demand for effective treatments. | Driver | High | Asthma / COPD |
| Growing health insurance coverage facilitates access to inhaled corticosteroids. | Driver | High | Prescription Outlets |
| Rising awareness of respiratory health creates opportunities for new entrants. | Opportunity | High | Hospital Pharmacies |
| The introduction of innovative inhaler devices presents a market entry point. | Opportunity | Medium | DPI |
| Regulatory delays in product approvals hinder market expansion. | Restraint | High | Fluticasone |
| High cost of inhaler prescriptions limits access for lower-income patients. | Restraint | Medium | Budesonide |
| Increased competition may pressure pricing strategies for existing products. | Challenge | Medium | Asthma / COPD |
| Supply chain disruptions can delay product availability in rural areas. | Challenge | High | Prescription Outlets |
Evaluation of Drivers in India Inhaled Corticosteroids Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| High prevalence of asthma and COPD increases medication demand. | Asthma / COPD | Around 15 million individuals in India are affected by asthma. |
| Health insurance coverage expansion improves access to inhalers. | Prescription Outlets | The Pradhan Mantri Ayushman Bharat Yojana provides coverage for respiratory treatments. |
| Awareness campaigns increase understanding of respiratory health. | Hospital Pharmacies | The Indian Medical Association promotes awareness about the importance of inhaled corticosteroids. |
| New inhaler devices attract more patients seeking effective treatments. | DPI | The average cost of a monthly inhaler prescription is approximately INR 1,500 to INR 2,000. |
| Guidelines for rational use of inhaled corticosteroids improve treatment protocols. | Fluticasone | The Drug Technical Advisory Board issued guidelines in 2021. |
The Inhaled Corticosteroids market in India is expanding as health insurance coverage increases, improving access to essential treatments. Approximately 15 million individuals are affected by asthma, creating a strong demand for effective medications. The introduction of new inhaler devices is attracting more patients seeking effective treatments. Guidelines from the Drug Technical Advisory Board are improving treatment protocols across healthcare facilities. Awareness campaigns led by the Indian Medical Association are increasing understanding of respiratory health, further driving demand. The Pradhan Mantri Ayushman Bharat Yojana is enhancing access to inhalers for economically disadvantaged families.
Evaluation of Restraints in India Inhaled Corticosteroids Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory delays in product approvals hinder market expansion. | Fluticasone | The Central Drugs Standard Control Organization regulates the approval process, causing delays. |
| High cost of inhaler prescriptions limits access for lower-income patients. | Budesonide | The average monthly cost of INR 1,500 to INR 2,000 is prohibitive for many. |
| Increased competition pressures pricing strategies for existing products. | Asthma / COPD | New entrants are affecting the pricing strategies of established inhalers. |
| Supply chain disruptions can delay product availability in rural areas. | Prescription Outlets | Logistical challenges impact distribution to remote healthcare facilities. |
| Limited awareness in rural areas restricts market growth potential. | DPI | Educational initiatives are still needed to inform patients about available treatments. |
India Inhaled Corticosteroids Market Challenges
The India Inhaled Corticosteroids Market faces notable technology-related delays, with the average cost of a monthly inhaler prescription ranging from INR 1,500 to INR 2,000, making it unaffordable for many low-income patients. Regulatory hurdles arise from the stringent approval processes enforced by the Central Drugs Standard Control Organization, which can prolong market entry for new inhaled corticosteroids, limiting access for patients. Supply chain issues stem from inconsistent availability of key ingredients, causing production delays and resulting in shortages for hospitals and clinics. Limited training for healthcare professionals restricts effective asthma management, leading to inadequate patient education on inhaler usage and adherence.
Trends in the India Inhaled Corticosteroids Market
Four trends stand out in the India Inhaled Corticosteroids Market.
- Shift from Traditional to Digital Health Solutions: India is experiencing a shift towards digital health solutions, with telemedicine platforms gaining popularity for respiratory consultations. In 2022, over 25% of asthma patients accessed care through telehealth services.
- Transition from MDI to DPI: The market is transitioning from Metered Dose Inhalers (MDIs) to Dry Powder Inhalers (DPIs) as patients prefer easier-to-use devices. DPI sales are projected to grow at a CAGR of 7.4% from 2026 to 2032.
- Increased Focus on Pediatric Asthma Management: Healthcare providers are increasingly focusing on pediatric asthma management, with Budesonide being widely prescribed for children. In 2021, pediatric prescriptions accounted for 25% of inhaled corticosteroid sales.
- Emergence of Combination Therapies: Combination therapies are becoming more prevalent in asthma management, particularly Fluticasone in conjunction with long-acting bronchodilators. This approach is expected to improve treatment efficacy and patient compliance.
Investment Opportunities in the India Inhaled Corticosteroids Market
Investors looking at the India Inhaled Corticosteroids Market should consider the following areas.
- Joint Ventures for Local Manufacturing: Local partnerships for manufacturing inhaled corticosteroids can address supply gaps. The average monthly cost of INR 1,500 to INR 2,000 presents an opportunity for cost-effective production in India.
- Investment in New Inhaler Technology: Investing in new inhaler technologies can meet growing demand. The Indian Council of Medical Research's guidelines support the introduction of advanced inhaler devices for better patient outcomes.
- Focus on Rural Healthcare Initiatives: With 15 million asthma patients, targeting rural healthcare initiatives is essential. Collaborating with local health authorities can facilitate access to inhaled corticosteroids in underserved areas.
- Expansion of Health Insurance Coverage: The ongoing expansion of health insurance coverage presents an opportunity. The Pradhan Mantri Ayushman Bharat Yojana can increase access to inhaled corticosteroids for economically disadvantaged families.
Government Initiatives in the India Inhaled Corticosteroids Market
The National Health Policy 2020 aims to reduce the burden of respiratory diseases through improved healthcare access and awareness programs, implemented by the Ministry of Health and Family Welfare. This policy strengthens the regulatory framework for inhaled corticosteroids, ensuring better quality and safety standards. Additionally, the Drug Technical Advisory Board issued guidelines in 2021 to promote the rational use of inhaled corticosteroids, improving treatment protocols across healthcare facilities. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) was updated in 2021 to include respiratory health initiatives, targeting urban and rural populations.
In 2022, the Pradhan Mantri Ayushman Bharat Yojana provided health insurance coverage for respiratory treatments, including inhaled corticosteroids, to economically disadvantaged families. The National Health Mission supports initiatives focused on improving respiratory health services across India, with funding allocated for awareness programs. The Central Drugs Standard Control Organization plays a role in regulating the approval and distribution of inhaled corticosteroids, ensuring compliance with safety standards. The National Institute of Health and Family Welfare launched a training program in 2022 for healthcare professionals on the effective use of inhaled corticosteroids in respiratory diseases.
Future Insight of the India Inhaled Corticosteroids Market
The India Inhaled Corticosteroids Market is set to evolve by 2032, driven by initiatives from the National Health Mission aimed at enhancing respiratory health services. Advanced inhaler technologies will improve patient adherence and treatment outcomes, making management more effective. Awareness campaigns by the Indian Medical Association will educate the public on the importance of inhaled corticosteroids, boosting demand. The NPCDCS's focus on respiratory health will likely improve access to treatment and management of respiratory diseases across both urban and rural areas.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Drug Name/Form – Fluticasone Dominated, Budesonide Expected to Grow Fastest
According to Shubham Deep, Research Manager at 6Wresearch, Fluticasone took a 53% share of drug name/form in 2025, more than any other category. Fluticasone holds the largest market share due to its widespread prescription for both asthma and COPD, making it a go-to choice among healthcare providers. Its established presence in treatment protocols, particularly in urban healthcare settings, solidifies its position as a preferred inhaled corticosteroid. The quickest growth will come from Budesonide, forecast to expand at a CAGR of 8.5% between 2026 and 2032. Budesonide is experiencing rapid growth as it is increasingly recognised for its effectiveness in managing asthma, particularly in pediatric patients. The rising awareness and initiatives by healthcare organisations to promote asthma management contribute to its expanding market presence. Suppliers should focus on increasing the availability of Budesonide to capitalise on its growing demand in the asthma management segment.
By Indication – Asthma / COPD Dominated, Long-Term Inflammation Expected to Grow Fastest
Asthma / COPD accounted for a 40% market share by indication in 2025. Asthma and COPD dominate the inhaled corticosteroids market because of their high prevalence in India, affecting approximately 15 million individuals. The focus on these conditions is critical, as they are leading causes of morbidity, particularly in urban settings. Over 2026–2032, Long-Term Inflammation is expected to post the fastest growth, at a CAGR of 8.0%. The long-term inflammation segment is growing quickly as healthcare providers place greater emphasis on managing chronic inflammatory conditions associated with asthma and COPD. This growth is supported by recent guidelines from the Indian Council of Medical Research that advocate for comprehensive treatment approaches. This trend indicates that suppliers should enhance their product offerings to address the increasing demand for long-term inflammation management solutions.
By Dosage Delivery – MDI Dominated, DPI Expected to Grow Fastest
MDI held a 41% share of the India Inhaled Corticosteroids Market by dosage delivery in 2025. MDI holds the largest share in the inhaled corticosteroids market due to its convenience and effectiveness, making it the preferred choice for many patients. The widespread adoption of MDIs in both urban and rural healthcare settings further reinforces its market dominance. DPI is projected to grow fastest, at a CAGR of 7.4% during 2026–2032. DPI is experiencing the fastest growth as it offers a user-friendly alternative for patients, particularly those with asthma, who prefer dry powder formulations. The increasing availability of DPI products is driving this segment's rapid expansion. Suppliers should consider expanding their DPI offerings to meet the rising demand for alternative delivery methods among patients.
By Distribution Channel – Prescription Outlets Dominated, Hospital Pharmacies Expected to Grow Fastest
In 2025, Prescription Outlets led the distribution channel split with a 48% share. Prescription outlets hold a substantial share of the inhaled corticosteroids market, acting as the main access point for patients to obtain their medications. The requirement for prescriptions from healthcare professionals ensures that patients receive appropriate treatment and monitoring. Hospital Pharmacies are set to record the highest CAGR in this split, 7.2% over 2026–2032. Hospital pharmacies are rapidly gaining traction as a vital distribution channel, especially for inpatient care of patients with severe asthma or COPD. The increase in hospital admissions for respiratory issues is propelling this segment's growth. Suppliers must prioritise partnerships with hospital pharmacies to ensure the timely availability of inhaled corticosteroids for patients requiring inpatient management.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Inhaled Corticosteroids Market Outlook
- Market Size of India Inhaled Corticosteroids Market, 2025
- Forecast of India Inhaled Corticosteroids Market, 2032
- Historical Data and Forecast of India Inhaled Corticosteroids Revenues & Volume for the Period 2022 - 2032F
- India Inhaled Corticosteroids Market Trend Evolution
- India Inhaled Corticosteroids Market Drivers and Challenges
- India Inhaled Corticosteroids Price Trends
- India Inhaled Corticosteroids Porter's Five Forces
- India Inhaled Corticosteroids Industry Life Cycle
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Drug Name/Form for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Budesonide for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Fluticasone for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Beclomethasone for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Mometasone for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Indication for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Asthma / COPD for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Long-Term Inflammation for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Allergies / Wheezing for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Nasal / Respiratory for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Dosage Delivery for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Nebulizer / Inhaler for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By DPI for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By MDI for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Nasal Spray / Inhaler for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Distribution Channel for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Prescription Outlets for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Hospital Pharmacies for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By Drugstores for the Period 2022 - 2032F
- Historical Data and Forecast of India Inhaled Corticosteroids Market Revenues & Volume By ENT Clinics for the Period 2022 - 2032F
- India Inhaled Corticosteroids Import Export Trade Statistics
- Market Opportunity Assessment By Drug Name/Form
- Market Opportunity Assessment By Indication
- Market Opportunity Assessment By Dosage Delivery
- Market Opportunity Assessment By Distribution Channel
- India Inhaled Corticosteroids Top Companies Market Share
- India Inhaled Corticosteroids Competitive Benchmarking By Technical and Operational Parameters
- India Inhaled Corticosteroids Company Profiles
- India Inhaled Corticosteroids Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Drug Name/Form
- Budesonide
- Fluticasone
- Beclomethasone
- Mometasone
By Indication
- Asthma / COPD
- Long-Term Inflammation
- Allergies / Wheezing
- Nasal / Respiratory
By Dosage Delivery
- Nebulizer / Inhaler
- DPI
- MDI
- Nasal Spray / Inhaler
By Distribution Channel
- Prescription Outlets
- Hospital Pharmacies
- Drugstores
- ENT Clinics
